Ubs Oconnor LLC Infla Rx N.V. Transaction History

Ubs Oconnor LLC

$2.23 Billion
Q2 2025

A detailed history of Ubs Oconnor LLC transactions in Infla Rx N.V. stock. As of the latest transaction made, Ubs Oconnor LLC holds 150,000 shares of IFRX stock, worth $124,500. This represents 0.01% of its overall portfolio holdings.

Number of Shares

150,000

Holding current value

$124,500

% of portfolio

0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.73 - $1.85 $67,106 - $170,064	91,927 Added 158.3%	150,000 $118,000
Q1 2025 May 15, 2025	SELL	$1.02 - $2.62 $578,866 - $1.49 Million	-567,516 Reduced 90.72%	58,073 $59,000
Q4 2024 Feb 14, 2025	SELL	$1.38 - $2.64 $237,756 - $454,837	-172,287 Reduced 21.59%	625,589 $1.56 Million
Q3 2024 Nov 14, 2024	BUY	$1.34 - $1.73 $101,984 - $131,666	76,108 Added 10.54%	797,876 $1.22 Million
Q2 2024 Aug 14, 2024	BUY	$1.18 - $1.74 $400,443 - $590,484	339,359 Added 88.74%	721,768 $1.26 Million
Q1 2024 May 15, 2024	BUY	$1.47 - $2.03 $265,377 - $366,473	180,529 Added 89.42%	382,409 $588,000
Q4 2023 Feb 14, 2024	SELL	$1.25 - $2.75 $235,150 - $517,330	-188,120 Reduced 48.24%	201,880 $329,000
Q3 2023 Nov 14, 2023	BUY	$2.66 - $4.33 $226,100 - $368,050	85,000 Added 27.87%	390,000 $1.16 Million
Q2 2023 Aug 14, 2023	BUY	$2.05 - $6.1 $625,250 - $1.86 Million	305,000 New	305,000 $1.36 Billion

Others Institutions Holding IFRX

# of Institutions

Shares Held

17.5M

Call Options Held

32.7K

Put Options Held

Suvretta Capital Management, LLC New York, NY

6.48M
Shares

$5.38 Million
0.18% of portfolio
683 Capital Management, LLC New York, NY

2.48M
Shares

$2.05 Million
0.15% of portfolio
Ra Capital Management, L.P. Boston, MA

1.97M
Shares

$1.64 Million
0.03% of portfolio
Eversept Partners, LP New York, NY

1.64M
Shares

$1.36 Million
0.13% of portfolio
Woodline Partners LP San Francisco, CA

751K
Shares

$623,551
0.0% of portfolio

View Full List

About InflaRx N.V.

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $36.7M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

More about IFRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account